Neurobiology of periventricular leukomalacia in the premature infant

J J Volpe1

  • 1Department of Neurology, Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. joseph.volpe@tch.harvard.edu

Pediatric Research
|October 20, 2001
PubMed

Insights

Preventing periventricular leukomalacia (PVL) in premature infants is achievable through understanding its causes. Targeting free radical damage and glutamate toxicity in vulnerable oligodendroglial precursor cells offers new therapeutic strategies.

Area of Science:

  • Neonatal neurology
  • Neurobiology
  • Developmental neuroscience

Background:

  • Periventricular leukomalacia (PVL) is a significant cause of neurologic disability in premature infants.
  • Understanding the pathogenesis of PVL is crucial for developing preventive strategies.

Purpose of the Study:

  • To elucidate the neurobiologic mechanisms underlying PVL pathogenesis.
  • To identify potential targets for preventing PVL in premature infants.

Main Methods:

  • Review of recent neurobiologic studies on PVL pathogenesis.
  • Analysis of the role of vascular factors, oligodendroglial precursor cell vulnerability, free radicals, and glutamate toxicity.

Main Results:

  • PVL pathogenesis involves interacting factors: immature cerebral vasculature, impaired cerebral blood flow regulation, and maturation-dependent vulnerability of oligodendroglial (OL) precursor cells.
  • OL precursor cells are susceptible to free radical and glutamate-mediated injury during a specific developmental window.
  • Factors like intraventricular hemorrhage, infection, inflammation, and cytokines contribute to PVL.

Conclusions:

  • New insights into PVL pathogenesis suggest potential preventive interventions.
  • Strategies include avoiding cerebral ischemia, using free radical scavengers, glutamate receptor antagonists, and managing maternal/fetal inflammation.